• 1. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 2. Distributed research: a new paradigm for undergraduate research and global problem solving?
  Bruce Parkinson Energy Environ. Sci., 2010,3, 509-511
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
• 5. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962

Introduction to (S)-1-(2-Methoxypyridin-4-yl)ethanamine Hydrochloride (CAS No. 1914157-93-9)

(S)-1-(2-Methoxypyridin-4-yl)ethanamine hydrochloride, with the CAS number 1914157-93-9, is a specialized chemical compound that has garnered significant attention in the field of pharmaceutical research and development. This compound belongs to the class of amine derivatives and features a unique structural motif that includes a pyridine ring substituted with a methoxy group at the 2-position and an amine group at the 4-position. The hydrochloride salt form enhances its solubility and stability, making it a valuable intermediate in synthetic chemistry and drug design.

The< strong>pyridine core of this molecule is a privileged scaffold in medicinal chemistry due to its ability to interact with biological targets through hydrogen bonding and hydrophobic interactions. The presence of the< strong>2-methoxypyridin-4-yl moiety not only influences the electronic properties of the molecule but also its binding affinity to various enzymes and receptors. This structural feature has been exploited in the design of novel pharmacophores targeting a wide range of therapeutic areas, including central nervous system disorders, inflammatory diseases, and cancer.

In recent years, there has been a surge in research focused on developing small-molecule modulators that can selectively interact with biological pathways involved in disease progression. The< strong>(S)-configuration of the amine group in this compound is particularly noteworthy, as enantioselective pharmacology plays a crucial role in determining the efficacy and safety of drug candidates. The (S)-enantiomer, in particular, has shown promising results in preclinical studies due to its enhanced binding affinity and reduced off-target effects compared to its (R)-counterpart.

One of the most compelling aspects of (S)-1-(2-methoxypyridin-4-yl)ethanamine hydrochloride is its potential application in the development of next-generation therapeutics. Recent studies have demonstrated its utility as a key intermediate in the synthesis of kinase inhibitors, which are critical for treating various forms of cancer. The< strong>pyridine ring and its substituents provide a suitable framework for designing molecules that can selectively inhibit aberrant signaling pathways involved in tumor growth and metastasis.

The< strong>hydrochloride salt form of this compound offers several advantages over its free base form, including improved pharmacokinetic properties such as enhanced solubility in aqueous solutions and increased bioavailability upon oral administration. These characteristics make it an attractive candidate for further development into an oral therapeutic agent. Additionally, the stability of the hydrochloride salt ensures that the compound remains viable during storage and transportation, which is essential for commercialization purposes.

The synthesis of (S)-1-(2-methoxypyridin-4-yl)ethanamine hydrochloride involves multi-step organic transformations that require careful optimization to achieve high yields and purity. Advanced synthetic methodologies, such as asymmetric hydrogenation and palladium-catalyzed cross-coupling reactions, have been employed to construct the desired stereocenter and functional groups with high enantioselectivity. These synthetic strategies not only highlight the compound's complexity but also showcase the advancements in synthetic chemistry that enable the production of complex molecular entities.

In conclusion, (S)-1-(2-methoxypyridin-4-yl)ethanamine hydrochloride represents a significant advancement in pharmaceutical chemistry due to its unique structural features and promising biological activity. Its potential applications in treating various diseases, coupled with its favorable pharmacokinetic properties, make it a compelling candidate for further investigation. As research continues to uncover new therapeutic targets and develop innovative drug design strategies, compounds like this will play an increasingly important role in shaping the future of medicine.

• 1914157-92-8((R)-1-(2-Methoxypyridin-4-yl)ethanamine dihydrochloride)
• 148900-69-0((2-Methoxypyridin-4-yl)methanamine)
• 1029689-75-5((2-Methoxypyridin-4-yl)methanamine dihydrochloride)
• 1060807-28-4(6-Methoxy-4-pyridineethanamine Hydrochloride)
• 1640848-91-4((2S)-2-Amino-2-(2-methoxypyridin-4-yl)ethanol)
• 1060807-38-6(2-(2-Methoxypyridin-4-YL)propan-2-amine)
• 1212853-72-9((1S)-1-(2-methoxypyridin-4-yl)ethan-1-amine)
• 1213559-80-8((1R)-1-(2-methoxypyridin-4-yl)ethan-1-amine)
• 1640848-93-6((R)-2-Amino-2-(2-methoxypyridin-4-yl)ethanol dihydrochloride)
• 149532-90-1((2-Methoxypyridin-4-yl)methanamine hydrochloride)